For immediate release

PRESS RELEASE

BOOST Pharma announces additional funding to advance its first-in-class therapy to treat rare bone disease Osteogenesis Imperfecta

- Syndicate formed by Industrifonden and Karolinska Development, Sweden
- Funds to support further clinical development, including defining its U.S. strategy

Copenhagen, May 28, 2024. BOOST Pharma, a clinical-stage biopharmaceutical company focused on the development of novel cell therapy treatments, announces today that it has raised additional funding from new investors Industrifonden and Karolinska Development.

BOOST Pharma is developing a first-in-class and potentially groundbreaking cell-based treatment for the congenital disease Osteogenesis Imperfecta (OI), also known as brittle bone disease, a condition characterized by fragile bones, constant fractures and bone deformity. This novel cell therapy is based on mesenchymal stem cells (MSCs) with high bone-forming capabilities. The treatment is designed to be administered directly upon diagnosis, either before or right after birth, providing a potential first-in-class advantage in the early years of life, when most bone fractures occur.

The OI therapy in development has received Rare Pediatric Disease designation in the U.S. and Orphan Drug Designation in both the U.S. and EU, and is in the final stages of a clinical Phase 1/2 study. The study results will be announced later in 2024.

"*BOOST Pharma originates from collaborative research at Stockholm-based Karolinska Institute, a world leader in cell therapy research. It is therefore very encouraging to having two key investors from Sweden joining our efforts to bring a potential therapy to those children suffering from OI*" said Evert Kueppers, Chief Executive Office of BOOST Pharma.

"*The treatment has a unique position in a field, where there are currently no treatment options and we are happy to include BOOST Pharma in our portfolio*," says Viktor Drvota, CEO of Karolinska Development.

"*Industrifonden is proud to support the BOOST team in its efforts to develop a therapy that brings hope for improving the quality of life of children born with OI*" says Jonathan Ilicki, Principal at Industrifonden.

NOTES FOR EDITORS

About BOOST Pharma

Supported by the BioInnovation Institute (BII) in Copenhagen, Denmark, BOOST Pharma is a clinical-stage biopharmaceutical company focused on the development of novel cell therapy treatments. The company is currently developing a first-in-class therapy to treat Osteogenesis Imperfecta, a serious, inherited rare genetic disease leading to severe physical disability.

About Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI), also know as Brittle Bone Disease, is a rare and devastating genetic disease, with currently no approved therapies. OI is characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints, and weakened teeth. In severe cases, those with OI may experience hundreds of fractures in a lifetime. In addition, people with OI often suffer muscle weakness, early hearing loss, fatigue, curved bones, scoliosis, respiratory problems, and short stature, leading to significant effects on overall health and quality of life. Current treatment of OI is only supportive, focusing on minimizing fractures and maximizing mobility, but to date, there are no FDA or EU approved treatments. OI is estimated to affect between 1 in 15,000 people globally.

For further information, please contact:

Evert Kueppers, CEO
Email: evert.kueppers@boostpharma.com